New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis

This early-phase trial tests a combination of two drugs, tagraxofusp and pacritinib, in about 20 adults with myelofibrosis (a bone marrow disorder) who have already tried standard JAK inhibitors or cannot use them. The main goals are to see if the combo can shrink an enlarged spleen and improve symptoms like fatigue and pain. Researchers will also monitor side effects and overall feasibility.